HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm to Recover Losses Due to Alleged Securities FraudNewsfile Corp • 05/17/21
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)PRNewsWire • 05/13/21
ACAD INVESTORS WHO LOST MONEY: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys NowNewsfile Corp • 05/10/21
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys NowNewsfile Corp • 05/05/21
ACAD INVESTOR DEADLINE: HAGENS BERMAN, National Trial Attorneys, Advises Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action FiledNewsfile Corp • 04/29/21
ACAD Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Shareholders to Contact the FirmBusiness Wire • 04/29/21
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Acadia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACADBusiness Wire • 04/27/21
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) InvestorsBusiness Wire • 04/26/21
Shareholder Alert: Robbins LLP Is Investigating Acadia Pharmaceuticals Inc. (ACAD) on Behalf of ShareholdersBusiness Wire • 04/23/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Pending, Deadline ApproachingNewsfile Corp • 04/23/21
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) InvestorsBusiness Wire • 04/23/21
The Law Offices of Frank R. Cruz Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of InvestorsBusiness Wire • 04/22/21
ACAD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Investors to Contact the FirmPRNewsWire • 04/22/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action FiledPRNewsWire • 04/22/21
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) on Behalf of InvestorsBusiness Wire • 04/21/21
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021Business Wire • 04/21/21
ACADIA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Acadia Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 04/21/21
Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACADPRNewsWire • 04/20/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law ViolationsNewsfile Corp • 04/14/21
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigation ACAD for Possible Securities Law ViolationsNewsfile Corp • 04/08/21
After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock DriversBenzinga • 04/06/21
